The latest price target for Corcept Therapeutics (NASDAQ:CORT) was reported by UBS on May 13, 2026. The analyst firm set a price target for $72.00 expecting CORT to rise to within 12 months (a possible 22.29% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Corcept Therapeutics (NASDAQ:CORT) was provided by UBS, and Corcept Therapeutics upgraded their buy rating.

The last upgrade for Corcept Therapeutics Inc happened on May 13, 2026 when UBS raised their price target to $72. UBS previously had a neutral for Corcept Therapeutics Inc.

There is no last downgrade for Corcept Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on May 13, 2026 so you should expect the next rating to be made available sometime around May 13, 2027.

While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a upgraded with a price target of $44.00 to $72.00. The current price Corcept Therapeutics (CORT) is trading at is $58.88, which is within the analyst’s predicted range.